10.76
+0.11(+1.03%)
Currency In USD
| Previous Close | 10.65 |
| Open | 10.83 |
| Day High | 10.94 |
| Day Low | 10.5 |
| 52-Week High | 32.1 |
| 52-Week Low | 7.65 |
| Volume | 21,635 |
| Average Volume | 143,583 |
| Market Cap | 206.71M |
| PE | -0.44 |
| EPS | -24.26 |
| Moving Average 50 Days | 10.3 |
| Moving Average 200 Days | 12.18 |
| Change | 0.11 |
If you invested $1000 in Lyell Immunopharma, Inc. (LYEL) since IPO date, it would be worth $31.85 as of August 24, 2025 at a share price of $10.76. Whereas If you bought $1000 worth of Lyell Immunopharma, Inc. (LYEL) shares 3 years ago, it would be worth $71.16 as of August 24, 2025 at a share price of $10.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
GlobeNewswire Inc.
Jul 25, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a sec
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
GlobeNewswire Inc.
Jun 23, 2025 9:00 PM GMT
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior man
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
GlobeNewswire Inc.
Jun 17, 2025 10:30 AM GMT
LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at